Eagle Bay Advisors’s Cardiff Oncology CRDF Stock Holding History

Eagle Bay Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-339	Closed	-$1.47K	–	296
2024 Q4	$1.47K	Hold	339	–	–	﹤0.01%	915
2024 Q3	$905	Hold	339	–	–	﹤0.01%	1293
2024 Q2	$753	Hold	339	–	–	﹤0.01%	948
2024 Q1	$1.81K	Hold	339	–	–	﹤0.01%	888
2023 Q4	$502	Hold	339	–	–	﹤0.01%	803
2023 Q3	$471	Hold	339	–	–	﹤0.01%	819
2023 Q2	$498	Hold	339	–	–	﹤0.01%	814
2023 Q1	$559	Hold	339	–	–	﹤0.01%	864
2022 Q4	$475	Hold	339	–	–	﹤0.01%	887
2022 Q3	$1K	Hold	339	–	–	﹤0.01%	814
2022 Q2	$746	Buy	+339	New	+$568	﹤0.01%	954
2022 Q1	–	Sell	-339	Closed	-$2K	–	438
2021 Q4	$2K	Hold	339	–	–	﹤0.01%	901
2021 Q3	$2K	Hold	339	–	–	﹤0.01%	927
2021 Q2	$3K	Buy	+339	New	+$2.88K	﹤0.01%	788

Other funds holding CRDF

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Eagle Bay Advisors's CRDF Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Cardiff Oncology (CRDF) in Q1 2025, closing a stake of 339 shares — an estimated $1.47K sold.

Eagle Bay Advisors first reported a position in CRDF in Q2 2021 and held it in 14 quarters. The position peaked at $3K in Q2 2021. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2025.

Eagle Bay Advisors reported no remaining Cardiff Oncology position as of Q1 2025 after selling out during the quarter.
Eagle Bay Advisors sold 339 Cardiff Oncology shares in Q1 2025, an estimated $1.47K.
Eagle Bay Advisors first reported a position in Cardiff Oncology in Q2 2021 and held it in 14 quarters.
Eagle Bay Advisors's Cardiff Oncology position peaked at $3K in Q2 2021.
116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.